RxDoctor Payments Data

Felicia McKnight, APRN

Family · Darlington, SCNPI 1942785019

Payments from drug & device makers

$1,301in general payments, 2019–2025

Across 58 payments — averaging $22.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$354
  • Amgen$216
  • AstraZeneca$178
  • Corcept Therapeutics$111
  • Abbott$83
  • Esperion Therapeutics, Inc.$58
  • plus $301 from 11 others

What the payments were for

  • Food & beverage$1,301100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,301 in reported general payments places this provider in the 70th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$3,813
Medicare patients
32
Services billed
359

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide27$38,668
TrulicityDulaglutide18$36,496
FarxigaDapagliflozin Propanediol12$20,284
JardianceEmpagliflozin12$18,955
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$17,829
MyrbetriqMirabegron11$11,820
NorvascAmlodipine Besylate12$11,374
LinzessLinaclotide12$8,934
Albuterol Sulfate HfaAlbuterol Sulfate32$1,274
Fluticasone Propionate49$817
Gabapentin37$566
Rosuvastatin Calcium42$551
Omeprazole42$537
Potassium Chloride32$515
Pravastatin Sodium28$502

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$354$38,66827 claims
Lilly USA, LLCTrulicity$54$36,49618 claims
AstraZenecaFarxiga$178$20,28412 claims
AbbVieLinzess$35$8,93412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,248 family providers in South Carolina.

Other family in Darlington

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →